Drugs / DS-7423
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01364844 | Jul 2011 → Nov 2013 | colorectal cancer, endometrial cancer | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-7423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01364844 ↗ |
| Action | Inhibit | “an Orally Administered Dual PI3K/mTOR Inhibitor” NCT01364844 ↗1“Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3545248 ↗ |
| Route | Oral | “oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily” NCT01364844 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3545248 ↗ |